Axcentua Pharmaceuticals AB

Stefan Rehnmark is appointed as CEO of Axcentua Pharmaceuticals

Pressmeddelande   •   Nov 10, 2010 15:30 CET

Dr. Stefan Rehnmark is appointed as new CEO of the company Axcentua Pharmaceuticals.
Dr. Anders Berkenstam has decided to resign after three years as CEO for Axcentua Pharmaceuticals as the company now is moving into a more operational mode. Dr. Berkenstam will remain as a member of the board of directors and a major shareholder.

“Dr. Berkenstam has as CEO and co-founder of Axcentua been instrumental in building the company and taking its lead compound AXP-107-11 into the first clinical trials in man Dr. Berkenstam has also been key to a series of successful financing rounds to enable the clinical studies” says Urban Paulsson, chairman of the board. “We are very happy that Stefan Rehnmark has accepted to take on the responsibility as the new CEO” says Urban Paulsson.

“I am very pleased to take on this responsibility and the challenge to move the company forward, continuing the clinical development of AXP107-11 within oncology as well as building the pipeline to ensure continued growth of the Company”, says Dr. Stefan Rehnmark.

About Axcentua Pharmaceuticals:

Axcentua Pharmaceuticals is a privately held early clinical development stage pharmaceutical company committed to the generation of investigational new drugs for diseases with high unmet medical need. The company was founded in 2007 by Dr. Anders Berkenstam, Dr. Stefan Rehnmark and Dr. Michael Robin Witt. Axcentua is pioneering a crystal re-engineering strategy of natural compounds as a novel approach in drug development. Candidate drugs can be developed faster, with less risk and at a fraction of the cost as compared to traditional drug development.

Natural compounds have a proven track record as drugs and represent a largely untapped resource of new drug development candidates. However, natural compounds may have unfavorable drug-like properties and intellectual property issues have hindered development of these compounds into successful drugs. By improving the drug-like qualities and obtaining IP on novel forms, Axcentua’s crystal re-engineering strategy opens up new opportunities to explore and develop this rich source of small molecule compounds into drugs with clear pharmaceutical benefits.

For further information please contact:
Urban Paulsson, Chairman
+ 46 8 200610
+46 702 250235

Dr. Stefan Rehnmark, CEO
+46 8 524 88 620
+46 73 6478842

www.axcentua.com

Axcentua is a privately held early clinical development stage pharmaceutical company committed to the rapid generation of investigational new drugs for diseases with high unmet medical need, with an initial focus on cancer. The Company is pioneering the field of "crystal re-engineering" of natural compounds as an alternative drug development strategy to arrive at novel drugs with clear clinical benefits more rapidly, with less risk and at a fraction of the cost compared to traditional drug development strategies.